ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Aqueous humour cytokine profiles in retinal vein occlusion: a comparative study of acute, chronic recurrent, and control eyes.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeThis study aimed to characterize inflammatory cytokine profiles in recurrent retinal vein occlusion (RVO) and to describe subtype- and phase-specific patterns relative to controls.
methodsThis was retrospective study conducted from September 2010 to September 2022 at the Japan Community Healthcare Organization Tokyo Shinjuku Medical Center and Jichi Medical University. Aqueous humour (AqH) was collected immediately before intravitreal bevacizumab, ranibizumab or aflibercept injections from patients with RVO. We included an acute group (RVO onset within 3 months) and a recurrent group (patients with disease duration of ≥ 1 year). Using a multiplex cytokine assay, we measured the concentrations of nine cytokines and VEGF. The results were compared with controls after adjusting for sex, age, axial length, and posterior vitreous detachment.
resultsAqH samples from 30 acute branch RVO (BRVO), 31 recurrent BRVO, 25 acute central RVO (CRVO), 20 recurrent CRVO, and 81 cataract surgery eyes without retinal disease (as controls) were used. In recurrent BRVO, MCP-1, CXCL13, and CCL11 levels were significantly lower than those in control eyes (all, P < 0.05). Similarly, in recurrent CRVO, MCP-1, CXCL12, CXCL13, CCL11, and CXCL1 levels were significantly reduced compared with controls (all, P < 0.05), whereas IL-6 levels were significantly elevated (P < 0.05). In acute RVO, cytokine alterations compared with controls were limited. Acute BRVO showed decreased MCP-1, CXCL13, and CCL11 levels (all, P < 0.05), while acute CRVO exhibited increased IL-6 and IP-10 levels (all, P < 0.05).
conclusionsInflammatory cytokine profiles in recurrent RVO differ between BRVO and CRVO and are characterized by reduced levels of multiple inflammatory cytokines compared with controls. These findings highlight distinct inflammatory features of recurrent RVO and provide a basis for future studies investigating disease progression and treatment resistance.
trial registrationUMIN000020718 https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_his_list.cgi?recptno=R000023907 . KEY MESSAGES: WHAT IS KNOWN: While anti- endothelial growth factor (VEGF) therapy is effective for treating cystic macular oedema (CME) secondary to retinal vein occlusion (RVO), the condition is not confined to the acute phase. The frequent chronicity and recurrence of CME imply that other pathological factors, beyond VEGF, are involved. Furthermore, preceding research on acute RVO has documented increased levels of inflammatory cytokines, including IL-6, IL-8, and MCP-1. WHAT IS NEW: Inflammatory cytokine profiles differ between branch RVO and central RVO in both acute and recurrent cases when each is explained relative to controls using multivariable-adjusted analyses. In particular, recurrent RVO is characterized by reduced levels of several inflammatory cytokines compared with controls, indicating a distinct inflammatory profile in the recurrent phase and providing insights into disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.